慢性肾脏病患者中非布司他相关肌病的风险
该回顾性队列研究纳入2014年2月至2016年1月在台北医学大学万芳医院使用非布司他的1332例患者,以时间平均eGFR为主要预测因子,肌病定义为用药期间肌酸激酶升高且非其他肌肉损伤所致。结果显示仅最低eGFR三分位与肌病显著相关(OR 4.21,95%CI 1.7–10.43),作者建议对CKD患者定期监测肌酸激酶。
要点
- 1332例使用非布司他的患者中1222例(91.7%)有CKD,41例发生非布司他相关肌病(3.2%)。
- 所有肌病患者均有CKD,CKD患者肌病发生率为0.013/100患者日(95%CI 0.01–0.02)。
- 最低eGFR三分位与肌病显著相关,OR 4.21(95%CI 1.7–10.43)。
核心结论
- 严重降低的eGFR患者使用非布司他时肌病风险更高。
- 建议定期监测肌酸激酶水平以早期发现非布司他相关肌病,尤其是CKD患者。
研究设计与样本
- 回顾性队列研究,纳入2014年2月至2016年1月在台北医学大学万芳医院使用非布司他的1332例患者。
- 主要预测因子为按2009年慢性肾脏病流行病学协作组公式计算的时间平均eGFR。
- 结局为非布司他相关肌病,定义为使用非布司他期间肌酸激酶升高且非其他肌肉损伤所致。
主要发现
- 非布司他使用中位时间为224天(第25、75百分位数:86、441.5天)。
- 1332例参与者中1222例(91.7%)有CKD,中位eGFR为20.8 ml/min per 1.73 m2(第25、75百分位数:9.0、35.4 ml/min per 1.73 m2)。
- 41例发生非布司他相关肌病(3.2%),所有肌病患者均有CKD,CKD患者肌病发生率为0.013/100患者日(95%CI 0.01–0.02)。
- 41例肌病患者中37例为肌炎,4例为横纹肌溶解。
- 17例停药后肌病缓解,8例继续非布司他治疗者肌病缓解。
临床怎么用
- 作者建议定期监测肌酸激酶水平以早期发现非布司他相关肌病,尤其是CKD患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Febuxostat, a nonpurine xanthine oxidase inhibitor, is widely used to treat hyperuricemia. Although febuxostat-associated rhabdomyolysis was reported in some patients with CKD, the association between CKD and febuxostat-associated myopathy remains uncertain. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Our retrospective cohort study included 1332 patients using febuxostat in Taipei Medical University-Wanfang Hospital from February of 2014 to January of 2016. The primary predictor was time-averaged eGFR as calculated by the equation proposed by the 2009 Chronic Kidney Disease Epidemiology Collaboration. The outcome was febuxostat-associated myopathy defined as elevated creatine kinase levels during febuxostat use that were not attributed to other muscular injuries. RESULTS: The median duration of febuxostat use was 224 days (25th, 75th percentiles: 86, 441.5 days). Of 1332 study participants, 1222 (91.7%) had CKD; the median eGFR was 20.8 ml/min per 1.73 m2 (25th, 75th percentiles: 9.0, 35.4 ml/min per 1.73 m2). Forty-one of the participants had febuxostat-associated myopathy (3.2%). All patients with myopathy had CKD, and the incident rate was 0.013 (95% confidence interval, 0.01 to 0.02) events per 100 patient-days in patients with CKD. Of 41 patients with myopathy, 37 had myositis, and four had rhabdomyolysis. Myopathy resolved in 17 patients who withdrew from treatment and eight patients who continued febuxostat treatment. Among the evaluated predictors, multivariate analysis showed that only the lowest eGFR tertile was significantly associated with myopathy in febuxostat users. The odds ratio of the lowest eGFR tertile to the highest tertile was 4.21 (95% confidence interval, 1.7 to 10.43). This finding remained consistent among subgroups stratified by age, sex, diabetes status, coronary artery disease, and statin or fibrate use. CONCLUSIONS: Patients with severely reduced eGFR had higher risk of myopathy with treatment of febuxostat. Regular monitoring of creatine kinase level is suggested for early detection of febuxostat-associated myopathy, particularly in patients with CKD.
引用
- Liu CT, Chen CY, Hsu CY, et al. Risk of Febuxostat-Associated Myopathy in Patients with CKD. Clin J Am Soc Nephrol. 2017. PMID: 28302902. doi:10.2215/CJN.08280816
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。